GHRH receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-26. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
=== Founding === National Semiconductor was founded in Danbury, Connecticut, by Dr. Bernard J. Rothlein on May 27, 1959, when he and seven colleagues, Edward N. Clarke, Joseph J. Gruber, Milton Schneider, Robert L. Hopkins, Robert L. Koch, Richard R. Rau and Arthur V. Siefert, left their employment at the semiconductor division of Sperry Rand Corporation. The founding of the new company was followed by Sperry Rand filing a lawsuit against National Semiconductor for patent infringement. By 1965, as it was reaching the courts, the preliminaries of the lawsuit had caused the stock value of National to be depressed. The depressed stock values allowed Peter J Sprague to invest heavily in the company with Sprague's family funds. Sprague also relied on further financial backing from a pair of West Coast investment firms and a New York underwriter to take control as the chairman of National Semiconductor. At that time Sprague was 27 years old. Jeffrey S. Young characterized the era as the beginning of venture capitalism. That same year National Semiconductor acquired Molectro. Molectro was founded in 1962 in Santa Clara, California, by J. Nall and D. Spittlehouse, who were formerly employed at Fairchild Semiconductor. The acquisition brought in two experts in linear semiconductor technologies, Robert Widlar and Dave Talbert, who were also formerly employed at Fairchild. The acquisition of Molectro provided National with the technology to launch itself in the fabrication and manufacture of monolithic integrated circuits.
Janeway (1873–1921) published results he had achieved using a laryngoscope he had recently developed. An American anesthesiologist practicing at Bellevue Hospital in New York City, Janeway was of the opinion that direct intratracheal insufflation of volatile anesthetics would provide improved conditions for otolaryngologic surgery. With this in mind, he developed a laryngoscope designed for the sole purpose of tracheal intubation. Similar to Jackson's device, Janeway's instrument incorporated a distal light source. Unique, however, was the inclusion of batteries within the handle, a central notch in the blade for maintaining the tracheal tube in the midline of the oropharynx during intubation and a slight curve to the distal tip of the blade to help guide the tube through the glottis. The success of this design led to its subsequent use in other types of surgery. Janeway was thus instrumental in popularizing the widespread use of direct laryngoscopy and tracheal intubation in the practice of anesthesiology. In 1928 Arthur Ernest Guedel introduced the cuffed endotracheal tube, which allowed deep enough anesthesia that completely suppressed spontaneously respirations while the gas and oxygen were delivered via positive pressure ventilation controlled by the anesthesiologist. Also important for the development of modern anesthesia are anesthesia machines. Only three years later Joseph W. Gale developed the technology where the anesthesiologist was able to ventilate only one lung at a time.
== Clinical significance == Mutations in SPINK1 has been associated with hereditary pancreatitis and tropical pancreatitis. Trypsinogen is normally created and stored an inactive zymogen of trypsin in the pancreas, but occasionally will autoactivate itself. PSTI serves to cleave prematurely activated trypsin to prevent the enzyme from causing cellular damage to the organ. Without the function of PSTI, the pancreas is subject to repeated episodes of damage. It has also been associated with prostate cancer.
leukocytes with specific granules), which include the neutrophils, innate lymphoid cells, mast cells, eosinophils, and basophils. Innate lymphoid cells (ILCs) derived from common lymphoid progenitor and belong to the lymphoid lineage. Mast cells reside in connective tissues and mucous membranes and regulate the inflammatory response. They are most often associated with allergy and anaphylaxis. Basophils and eosinophils are related to neutrophils. They secrete chemical mediators that are involved in defending against parasites and play a role in allergic reactions, such as asthma. Natural killer cells (NK cells) do not directly attack invading microbes but destroy compromised host cells, such as tumor cells or virus-infected cells. NK cells recognise such cells by a condition known as "missing self", which involves low levels of a cell-surface marker called MHC I (major histocompatibility complex)—a situation that can arise in viral infection. Normal body cells are not recognized and attacked by NK cells because they express intact self MHC antigens, which inhibit NK cell activity. Monocytes, upon moving to injured tissue, turn into dendritic cells and macrophages while promoting tissue healing. The major humoral component of the innate immune response is the complement system, a biochemical cascade that attacks the surfaces of foreign cells.
Sources: en.wikipedia.org
The Royal Marine battalion and Royal Marine Artillery were to go to Quebec under the command of Beckwith, leaving Napier a brigade of 1,000 infantry and three artillery pieces. It had been proposed to move the 102d to operations in the American south, but this was not carried out. Napier transferred by exchange to the 50th Regiment of Foot in September 1813. Detachments of the 102d Regiment of Foot remained on both sides of the border between the British colony of New Brunswick and the U.S. state of Maine after the war's end in December 1814 at Moose Island, modern day Eastport, Maine, United States. The Treaty of Ghent was signed on 24 December 1814 by the negotiators, ratified by the Prince Regent on 27 December, and by the United States President on 17 February, ending the war. After three years at New Brunswick, it embarked in the autumn of 1817 to return to England under the command of Major Gustavus Rochford. After the end of the wars against Napoleonic France and the United States, the British Army disbanded many units for the sake of economy. The regiment was reorganized as the 100th Regiment of Foot in 1816. The regiment was the last British unit to occupy the United States; the last detachments returned to Chatham in England, where the regiment was disbanded on 24 March 1818.
Neuromelanin (NM) is an insoluble polymer pigment produced in specific populations of catecholaminergic neurons in the brain. Humans have the largest amount of NM, which is present in lesser amounts in other primates, and totally absent in many other species. The biological function remains unknown, although human NM has been shown to efficiently bind transition metals such as iron, as well as other potentially toxic molecules. Therefore, it may play crucial roles in apoptosis and the related Parkinson's disease.
At a growth rate of 2% per year, an industrial civilization should stop growing quite early in its history (after a few centuries). In summary, the impossibility of sustainably securing energy resources may explain the absence of Type II and III civilizations. For Zoltan Galántai, it is not possible to imagine a civilization project that spans centuries (like a Dyson sphere) or even millions of years, unless one imagines a thought and an ethic different from ours, within the reach of an ancestral civilization. He therefore proposes to classify civilizations according to their ability to carry out large-scale civilization projects over the long term. Finally, for Freeman Dyson, communication and life can continue forever in an open Universe with a finite amount of energy; intelligence is therefore the only fundamental parameter for a civilization to survive in the very long term, and energy is then no longer what defines it, a thesis he develops in his article "Time Without End: Physics and Biology in an Open Universe".
== Structure and binding partners == Members of the CCN protein family, including CTGF, are structurally characterized by having four conserved, cysteine-rich domains. These domains are, from N- to C-termini, the insulin-like growth factor binding protein (IGFBP) domain, the von Willebrand type C repeats (vWC) domain, the thrombospondin type 1 repeat (TSR) domain, and a C-terminal domain (CT) with a cysteine knot motif. CTGF exerts its functions by binding to various cell surface receptors in a context-dependent manner, including integrin receptors, cell surface heparan sulfate proteoglycans (HSPGs), LRPs, and TrkA. In addition, CTGF also binds growth factors and extracellular matrix proteins. The N-terminal half of CTGF interacts with aggrecan, the TSR domain interacts with VEGF and, the CT domain interacts with members of the TGF-β superfamily, fibronectin, perlecan, fibulin-1, slit, and mucins.
=== Size, race, and ethnicity === Alleged differences in races have led to the creation of sexual myths. There is no scientific background to support the alleged "oversized" penis in black people. There is no indication that penis size differs between ethnicities. According to urologist Aaron Spitz, many websites and studies promoting variation of penis size between races use unscientific methods of collecting information and often ignore contradictory evidence. He concludes that "when you really take a good look at the naked data, there's not a whole lot there [showing racial variation in penis size]." A 2024 meta-analysis of 34,060 Chinese men found that while flaccid penis length was shorter on average than the global reference population, erect length showed no statistically significant difference. The study found that Chinese men had a higher average increase from flaccid to erect state (67%) compared to the global average (43%), meaning a greater proportion fell into the category colloquially known as "growers" rather than "showers." The authors noted this has implications for older cross-population studies, many of which relied on flaccid rather than erect measurements: populations with more "growers" would appear smaller in flaccid-based datasets even when erect dimensions are comparable. While some meta-analyses have identified modest average differences across geographic regions, the variation in penis size within any racial or ethnic group vastly exceeds the differences between groups.
Sources: en.wikipedia.org
They also included giving the Reserve Forces and Cadets Associations the power to produce an annual report to Parliament on the state of the volunteer reserves (the Royal Naval Reserve, The Royal Marines Reserve, the Army Reserve and the Royal Auxiliary Air Force). In January 2021, the Army Reserve trained strength stood at 26,820. (This figure excludes recruits undergoing phase 1 training and various non-deployable categories such as University Officers' Training Corps). During 2020, three reserve infantry battalions, 7 Rifles and 5 Fusiliers followed by 6 Rifles, provided the framework battalion for peacekeeping in Cyprus and over the winter 20/21 the Royal Yeomanry provided a composite squadron for a six-month tour on armoured reconnaissance as part of Britain's forward presence in Estonia. Army Reservists have a minimum commitment to serve 27 training days per year or 19 days for some national units. This period normally includes a two-week period of continuous training either as an Army Reserve unit, on courses or attached to a Regular unit. Army Reserve soldiers are paid at a similar rate to their regular equivalents while engaged on military activities.
The darker feathers of birds owe their color to melanin and are less readily degraded by bacteria than unpigmented ones or those containing carotenoid pigments. Feathers that contain melanin are also 39% more resistant to abrasion than those that do not because melanin granules help fill the space between the keratin strands that form feathers. Pheomelanin synthesis in birds implies the consumption of cysteine, a semi‐essential amino acid that is necessary for the synthesis of the antioxidant glutathione (GSH) but that may be toxic if in excess in the diet. Indeed, many carnivorous birds, which have a high protein content in their diet, exhibit pheomelanin‐based coloration. Melanin is also important in mammalian pigmentation. The coat pattern of mammals is determined by the agouti gene which regulates the distribution of melanin. The mechanisms of the gene have been extensively studied in mice to provide an insight into the diversity of mammalian coat patterns. Melanin in arthropods has been observed to be deposited in layers thus producing a Bragg reflector of alternating refractive index. When the scale of this pattern matches the wavelength of visible light, structural coloration arises: giving a number of species an iridescent color. Arachnids are one of the few groups in which melanin has not been easily detected, though researchers found data suggesting spiders do in fact produce melanin. Some moth species, including the wood tiger moth, convert resources to melanin to enhance their thermoregulation.
The Society had just acquired a scientific collection of diverse microorganisms (bacteria, viruses, fungi and protozoa) and related materials, known as the American Type Culture Collection. Rogers understood its research significance, and willingly moved the entire collection in a suitcase. Years later colleague John Alford would assert "No facet of Rogers' scientific career is more important to the microbiologist of today than his involvement with the American Type Culture Collection." Two years later the National Academy of Sciences took an interest in administering the collection, and today it remains a vital resource for biological research and medical applications.
18q deletion syndrome Acrodermatitis enteropathica Acrogeria (Gottron syndrome) Acrokeratosis verruciformis (acrokeratosis verruciformis of Hopf) Adams–Oliver syndrome Adducted thumbs syndrome Albright's hereditary osteodystrophy Angelman syndrome Apert syndrome (acrocephalosyndactyly) Arthrogryposis–renal dysfunction–cholestasis syndrome Ataxia telangiectasia (Louis–Bar syndrome) Atrichia with papular lesions (papular atrichia) Atrophodermia vermiculata (acne vermoulante, acne vermoulanti, atrophoderma reticulata symmetrica faciei, atrophoderma reticulatum, atrophoderma vermiculata, atrophoderma vermiculatum, atrophodermia reticulata symmetrica faciei, atrophodermia ulerythematosa, atrophodermie vermiculée des joues avec kératoses folliculaires, folliculitis ulerythema reticulata, folliculitis ulerythematous reticulata, folliculitis ulerythemosa, honeycomb atrophy, ulerythema acneforme, ulerythema acneiforme) Autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy syndrome Bart syndrome Bazex–Dupré–Christol syndrome (Bazex syndrome, follicular atrophoderma and basal cell carcinomas) Beare–Stevenson cutis gyrata syndrome Bloom syndrome (Bloom–Torre–Machacek syndrome) Blue rubber bleb nevus syndrome Brittle hair–intellectual impairment–decreased fertility–short stature syndrome Cantú syndrome Cardio-facio-cutaneous syndrome (cardiofaciocutaneous syndrome) Cartilage–hair hypoplasia (McKusick type metaphyseal chondrodysplasia) Cerebral dysgenesis–neuropathy–ichthyosis–keratoderma syndrome Childhood tumor syndrome Chondrodysplasia punctata Cicatricial junctional epidermolysis bullosa Craniosynostosis–anal anomalies–porokeratosis syndrome Cockayne syndrome Colobomas of the eye–heart defects–ichthyosiform dermatosis–mental retardation–ear defects syndrome (CHIME syndrome, Zunich neuroectodermal syndrome, Zunich–Kaye syndrome) Congenital hemidysplasia with ichthyosiform erythroderma and limb defects syndrome (CHILD syndrome) Conradi–Hünermann syndrome (Conradi–Hünermann–Happle syndrome, Happle syndrome, X-linked dominant chondrodysplasia punctata) Costello syndrome Cronkhite–Canada syndrome Crouzon syndrome Cutis verticis gyrata Darier's disease (Darier–White disease, dyskeratosis follicularis, keratosis follicularis) DeSanctis–Cacchione syndrome Disseminated superficial actinic porokeratosis Disseminated superficial porokeratosis Dolichol kinase deficiency Dominant dystrophic epidermolysis bullosa Dyskeratosis congenita (Zinsser–Cole–Engman syndrome) Dystrophic epidermolysis bullosa Ectodermal dysplasia Ectodermal dysplasia with corkscrew hairs Ectrodactyly–ectodermal dysplasia–cleft syndrome (EEC syndrome, split hand–split foot–ectodermal dysplasia–cleft syndrome) Epidermolysis bullosa herpetiformis (Dowling–Meara epidermolysis bullosa simplex) Epidermolysis bullosa simplex Epidermolysis bullosa simplex of Ogna Epidermolysis bullosa simplex with mottled pigmentation Epidermolysis bullosa simplex with muscular dystrophy Epidermolytic hyperkeratosis (bullous congenital ichthyosiform erythroderma, bullous ichthyosiform erythroderma) Erythrokeratodermia with ataxia (Giroux–Barbeau syndrome) Familial benign chronic pemphigus (familial benign pemphigus, Hailey–Hailey disease) Fanconi syndrome (familial pancytopenia, familial panmyelophthisis) Fibrodysplasia ossificans progressiva Focal dermal hypoplasia (Goltz syndrome) Follicular atrophoderma Franceschetti–Klein syndrome (mandibulofacial dysostosis) Gardner's syndrome (familial colorectal polyposis) Gastrocutaneous syndrome Generalized atrophic benign epidermolysis bullosa Generalized epidermolysis bullosa simplex (Koebner variant of generalized epidermolysis bullosa simplex) Generalized trichoepithelioma Giant axonal neuropathy with curly hair Gingival fibromatosis with hypertrichosis Haber syndrome Hallerman–Streiff syndrome Harlequin-type ichthyosis (harlequin baby, harlequin fetus, harlequin ichthyosis, ichthyosis congenita, ichthyosis congenita gravior) Hay–Wells syndrome (AEC syndrome, ankyloblepharon filiforme adnatum–ectodermal dysplasia–cleft palate syndrome, ankyloblepharon–ectodermal defects–cleft lip and palate syndrome, ankyloblepharon–ectodermal dysplasia–clefting syndrome) Hereditary sclerosing poikiloderma Heterochromia iridum Holocarboxylase synthetase deficiency Hypohidrotic ectodermal dysplasia (anhidrotic ectodermal dysplasia, Christ–Siemens–Touraine syndrome) Hypotrichosis–acro-osteolysis–onychogryphosis–palmoplantar keratoderma–periodontitis syndrome Hypotrichosis–lymphedema–telangiectasia syndrome Ichthyosis–brittle hair–impaired intelligence–decreased fertility–short stature syndrome (IBIDS syndrome, sulfur-deficient brittle hair syndrome, Tay's syndrome, trichothiodystrophy, trichothiodystrophy with ichthyosis) Ichthyosis bullosa of Siemens (ichthyosis exfoliativa) Ichthyosis follicularis (ichthyosis follicularis with alopecia and photophobia syndrome) Ichthyosis linearis circumflexa Ichthyosis prematurity syndrome Ichthyosis vulgaris (autosomal dominant ichthyosis, ichthyosis simplex) Ichthyosis with confetti Neonatal ichthyosis–sclerosing cholangitis syndrome (ichthyosis–sclerosing cholangitis syndrome, NISCH syndrome) Incontinentia pigmenti achromians (hypomelanosis of Ito) Immune dysfunction–polyendocrinopathy–enteropathy–X-linked syndrome Jaffe–Campanacci syndrome Johanson–Blizzard syndrome Johnson–McMillin syndrome Joubert syndrome Junctional epidermolysis bullosa Junctional epidermolysis bullosa gravis (epidermolysis bullosa letalis, Herlitz disease, Herlitz epidermolysis bullosa, Herlitz syndrome, lethal junctional epidermolysis bullosa) Junctional epidermolysis bullosa with pyloric atresia Kabuki syndrome (Kabuki makeup syndrome, Niikawa–Kuroki syndrome) Keratolytic winter erythema (erythrokeratolysis hiemalis, Oudtshoorn disease, Oudtshoorn skin) Keratosis follicularis spinulosa decalvans (Siemens-1 syndrome) Keratosis linearis with ichthyosis congenita and sclerosing keratoderma syndrome Keratosis pilaris atrophicans faciei (folliculitis rubra, keratosis pilaris rubra atrophicans faciei, lichen pilare, lichen pilaire ou xerodermie pilaire symmetrique de la face, ulerythema ophryogenes, xerodermi pilaire symmetrique de la face) Keratosis pilaris Kindler syndrome (acrokeratotic poikiloderma, bullous acrokeratotic poikiloderma of Kindler and Weary, congenital poikiloderma with blisters and keratoses, congenital poikiloderma with bullae and progressive cutaneous atrophy, hereditary acrokeratotic poikiloderma, hyperkeratosis–hyperpigmentation syndrome, Weary–Kindler syndrome) Klinefelter syndrome Klippel–Feil syndrome Lamellar ichthyosis (collodion baby) Legius syndrome (neurofibromatosis type 1-like syndrome) Lelis syndrome Lenz–Majewski syndrome Leschke syndrome Lethal acantholytic epidermolysis bullosa Lhermitte–Duclos disease Linear and whorled nevoid hypermelanosis (linear nevoid hyperpigmentation, progressive cribriform and zosteriform hyperpigmentation, reticulate and zosteriform hyperpigmentation, reticulate hyperpigmentation of Iijima and Naito and Uyeno, zebra-like hyperpigmentation in whorls and streaks, zebra-line hyperpigmentation) Linear Darier disease (acantholytic dyskeratotic epidermal nevus) Linear porokeratosis Localized epidermolysis bullosa simplex (Weber–Cockayne syndrome, Weber–Cockayne variant of generalized epidermolysis bullosa simplex) Mandibuloacral dysplasia Marinesco–Sjögren syndrome McCune–Albright syndrome McCusick syndrome Metageria Microphthalmia–dermal aplasia–sclerocornea syndrome Mitis junctional epidermolysis bullosa (nonlethal junctional epidermolysis bullosa) Mitochondrial myopathy–encephalopathy–lactic acidosis–stroke syndrome Multiple lentigines syndrome (cardiocutaneous syndrome, Gorlin syndrome II, lentiginosis profusa syndrome, LEOPARD syndrome, progressive cardiomyopathic lentiginosis) Multiple pterygium syndrome Multiple sulfatase deficiency (Austin disease, mucosulfatidosis) Naegeli–Franceschetti–Jadassohn syndrome (chromatophore nevus of Naegeli) Netherton syndrome Neurofibromatosis type 1 (von Recklinghausen's disease) Neurofibromatosis type 3 (neurofibromatosis mixed type) Neurofibromatosis type 4 (neurofibromatosis variant type) Neutral lipid storage disease (Dorfman–Chanarin syndrome) Nonbullous congenital ichthyosiform erythroderma (congenital ichthyosiform erythroderma) Noonan syndrome Oculocerebrocutaneous syndrome (Delleman–Oorthuys syndrome) Oculodentodigital dysplasia Odonto-tricho-ungual-digital-palmar syndrome Oliver–McFarlane syndrome Orofaciodigital syndrome Pachydermoperiostosis (idiopathic hypertrophic osteoathorpathy, Touraine–Solente–Gole syndrome) Peeling skin syndrome (acral peeling skin syndrome, continual peeling skin syndrome, familial continual skin peeling, idiopathic deciduous skin, keratolysis exfoliativa congenita) Pfeiffer syndrome Photosensitivity–ichthyosis–brittle sulfur-deficient hair–impaired intelligence–decreased fertility–short stature syndrome Pityriasis rotunda (pityriasis circinata, tinea circinata) Plate-like osteoma cutis Plaque-type porokeratosis (classic porokeratosis, porokeratosis of Mibelli) Polyneuropathy–organomegaly–endocrinopathy–monoclonal gammopathy–skin changes syndrome (Crow–Fukase syndrome) Polyostotic fibrous dysplasia (Albright's disease) Popliteal pterygium syndrome Porokeratosis Porokeratosis palmaris et plantaris disseminata Prader–Willi syndrome Progeria (Hutchinson–Gilford progeria syndrome, Hutchinson–Gilford syndrome, progeria syndrome) Progressive osseous heteroplasia Progressive symmetric erythrokeratodermia (erythrokeratodermia progressiva symmetrica) Proteus syndrome Proteus-like syndrome Punctate porokeratosis Rapp–Hodgkin syndrome (Rapp–Hodgkin ectodermal dysplasia syndrome) Recessive dystrophic epidermolysis bullosa (Hallopeau–Siemens variant of epidermolysis bullosa, Hallopeau–Siemens disease) Refsum's disease (heredopathia atactica polyneuritiformis, phytanic acid storage disease) Relapsing linear acantholytic dermatosis Restrictive dermopathy Rhizomelic chondrodysplasia punctata (autosomal recessive chondrodysplasia punctata type 1, chondrodystrophia calcificans punctata, peroxisomal biogenesis disorder complementation group 11) Rombo syndrome Rothmund–Thomson syndrome (poikiloderma congenitale) Rud syndrome Say syndrome Scalp–ear–nipple syndrome (Finlay–Marks syndrome) Schindler disease (Kanzaki disease, alpha-N-acetylgalactosaminidase deficiency) Schinzel–Giedion syndrome Scleroatrophic syndrome of Huriez (Huriez syndrome, palmoplantar keratoderma with scleroatrophy, palmoplantar keratoderma with sclerodactyly, scleroatrophic and keratotic dermatosis of the limbs, sclerotylosis) Segmental neurofibromatosis Senter syndrome (Desmons' syndrome) Shabbir syndrome (laryngo–onycho–cutaneous syndrome) Silver–Russell syndrome Sjögren–Larsson syndrome Skin fragility syndrome (plakophilin 1 deficiency) Smith–Lemli–Opitz syndrome Sturge–Weber syndrome Supernumerary nipples–uropathies–Becker's nevus syndrome Terminal osseous dysplasia with pigmentary defects Tooth and nail syndrome (hypodontia with nail dysgenesis, Witkop syndrome) Townes–Brocks syndrome Transient bullous dermolysis of the newborn Treacher Collins syndrome (Treacher Collins–Franceschetti syndrome) Tricho–dento–osseous syndrome Tricho–rhino–phalangeal syndrome Tuberous sclerosis (Bourneville disease, epiloia) Turner syndrome Ulnar–mammary syndrome Van Der Woude syndrome Von Hippel–Lindau syndrome Watson syndrome Werner syndrome (adult progeria) Westerhof syndrome Whistling syndrome (craniocarpotarsal syndrome, distal arthrogryposis type 2, Freeman–Sheldon syndrome, Windmill–Vane–Hand syndrome) Wilson–Turner syndrome Wolf–Hirschhorn syndrome (4p- syndrome) X-linked ichthyosis (steroid sulfatase deficiency, X-linked recessive ichthyosis) X-linked recessive chondrodysplasia punctata Xeroderma pigmentosum (Cockayne syndrome complex) XXYY genotype Zimmermann–Laband syndrome
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.